Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/16490Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Mitchell, Paul L R | - |
| dc.contributor.author | John, Thomas | - |
| dc.date | 2016-11-22 | - |
| dc.date.accessioned | 2017-01-09T04:37:14Z | - |
| dc.date.available | 2017-01-09T04:37:14Z | - |
| dc.date.issued | 2016-12 | - |
| dc.identifier.citation | Lancet Respiratory Medicine 2016; 4(12): 947-949 | en_US |
| dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/16490 | - |
| dc.title | Lung cancer in 2016: immunotherapy comes of age | en_US |
| dc.type | Journal Article | en_US |
| dc.identifier.journaltitle | Lancet Respiratory Medicine | en_US |
| dc.identifier.affiliation | Olivia Newton-John Cancer and Wellness Centre, Austin Health, Heidelberg, Victoria, Australia | en_US |
| dc.identifier.affiliation | Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia | en_US |
| dc.identifier.pubmeduri | https://pubmed.ncbi.nlm.nih.gov/27890503 | en_US |
| dc.identifier.doi | 10.1016/S2213-2600(16)30379-4 | en_US |
| dc.type.content | Text | en_US |
| dc.type.austin | Journal Article | en_US |
| local.name.researcher | John, Thomas | |
| item.openairetype | Journal Article | - |
| item.cerifentitytype | Publications | - |
| item.grantfulltext | none | - |
| item.fulltext | No Fulltext | - |
| item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
| crisitem.author.dept | Medical Oncology | - |
| crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
| crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
| crisitem.author.dept | Medical Oncology | - |
| crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
| Appears in Collections: | Journal articles | |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.